* Edwards Lifesciences Corp EW.N EW is expected to show
a fall
in quarterly revenue when it reports results on February 11 for
the period ending December 31 2024
* The Irvine California-based company is expected to report
a
11.5% decrease in revenue to $1.358 billion from $1.53 billion a
year ago, according to the mean estimate from 24 analysts, based
on LSEG data.The company's guidance on October 24 2024, for the
period ended December 31, was for revenue between $1.33 billion
and $1.39 billion.
* LSEG's mean analyst estimate for Edwards Lifesciences
Corp is
for earnings of 55 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 15 "strong buy" or "buy," 18
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Edwards
Lifesciences Corp is $78.07, above its last closing price
of $70.99.
The company's guidance on October 24 2024 for the period ended
December 31 was for gross profit margin of USD78%.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2024 0.63 0.64 0.67 Beat 4.6
Jun. 30 2024 0.70 0.69 0.70 Beat 0.9
Mar. 31 2024 0.64 0.64 0.66 Beat 2.7
Dec. 31 2023 0.64 0.64 0.64 Met 0.4
Sep. 0.59 0.59 0.59 Met -0.4
30 2023
Jun. 30 2023 0.65 0.65 0.66 Beat 2
Mar. 31 2023 0.61 0.61 0.62 Beat 2.1
Dec. 31 2022 0.62 0.61 0.64 Beat 4.5
This summary was machine generated February 7 at 21:18 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)